




Research Foundation

Lymphoma Rounds at Lymphoma, Leukemia & Myeloma Congress

October 14, 2026

Planning Committee
and Faculty Biographies

Table of Contents

Planning Committee Members	3
Lymphoma Rounds Advisory Board Members	4
Program Agenda	5
Planning Committee and Faculty Biographies	7

Educational Grant Sponsors



Planning Committee Members

Kieron Dunleavy, MD

MedStar Georgetown University Hospital

Mark Roschewski, MD,

Memorial Sloan Kettering Cancer Center

Eduardo Sotomayor, MD**

Tampa General Hospital

**** Denotes Lymphoma Research Foundation Current and/or Former Grantee**

Lymphoma Rounds Advisory Board (LRAB)

Reem Karmali, MD, Northwestern University (Co-Chair)**

Paul S. Martin, MD, Fred Hutchinson Cancer Center/UW Medical Center (Co-Chair)

Jeremy Abramson, MD, MSc, Massachusetts General Hospital Cancer Center

Sairah Ahmed, MD, MD Anderson Cancer Center

Stefan Barta, MD, MS, MRCP, University of Pennsylvania

Elizabeth Brem, MD, University of California, Irvine**

John Burke, MD, Rocky Mountain Cancer Centers

Jonathon Cohen, MD, Emory University**

Kieron Dunleavy, MD, MedStar Georgetown University Hospital

James Gerson, MD, University of Vermont

Eric Hsi, MD, Mayo Clinic, Rochester

Michael Khodadoust, MD, PhD, Stanford University Medical Center

Justin Kline, MD, The University of Chicago

Andrew Lipsky, MD, Columbia University Medical Center

Krish Patel, MD, Sarah Cannon Research Institute

Mark Roschewski, MD, Memorial Sloan Kettering Cancer Center

Allison Rosenthal, DO, Mayo Clinic, Phoenix**

Stephen Schuster, MD, University of Pennsylvania

Eduardo Sotomayor, MD, Tampa General Hospital**

Frédérique St-Pierre, MD, CM, Great River Health

Gita Thanarajasingam, MD, Mayo Clinic, Rochester**

Victor Yazbeck, MD, MS, Virginia Commonwealth University**

** Denotes Lymphoma Research Foundation Current and/or Former Grantee

Program Agenda

Wednesday, October 14 2026

All times are listed in Eastern Standard Time

7:00 PM **Opening Remarks**

Eva Migliore, Lymphoma Research Foundation

7:05 PM **Keynote Presentation: Delivering Bispecific Antibodies for Mantle Cell Lymphoma Patients in a Community Practice Setting**

Anita Kumar, MD, Memorial Sloan Kettering Cancer Center

7:25 PM **Multidisciplinary Case-Based Panel Discussion**

Session Chair

Mark Roschewski, MD, Memorial Sloan Kettering Cancer Center

Case Presenters

Diffuse Large B-Cell Lymphoma

Pratik Shah, MD, Northwell Health

Hodgkin Lymphoma Therapy in Patients with Cardiac Comorbidities

Jason Avigan, MD, NYU Langone Health

Panelists

Nilanjan Ghosh, MD, PhD, Atrium Health Levine Cancer Institute

Andrew Ip, MD, Hackensack John Theurer Cancer Center

Anju Nohria, MD, NYU Langone Health

Sarah Rutherford, MD, NYU Langone Health

Program Agenda

Wednesday, October 14 2026

All times are listed in Eastern Standard Time

8:10 PM Special Presentation: CAR-T Referral Pathways

Speaker

Luca Paruzzo, MD, *University of Pennsylvania*

Moderator

Stephen Schuster, MD, *University of Pennsylvania*

Panelists

Kieron Dunleavy, MD, *Medstar Georgetown University Hospital*

Nilanjan Ghosh, MD, PhD, *Atrium Health Levine Cancer Institute*

Eduardo Sotomayor, MD, *Tampa General Hospital*

8:30 PM Program Adjourns

Planning Committee Biographies

Kieron Dunleavy, MD

MedStar Georgetown University Hospital

Kieron Dunleavy is Director of Hematologic Malignancies at Lombardi Cancer Center and Professor of Medicine at Georgetown University. He is a medical oncologist who completed fellowships in Dublin, Ireland and subsequently at the National Cancer Institute (NCI), Bethesda, Maryland. Dr. Dunleavy is an expert in lymphoid malignancies, and his work has focused on the biology and treatment of lymphoid diseases. His interests include aggressive lymphomas including primary mediastinal and high-grade lymphomas as well as viral/microbial associated lymphoid diseases and he has published extensively in these areas. He is currently the principal investigator on several lymphoma studies and serves on the ECOG lymphoma committee and on the scientific advisory board of the Lymphoma Research Foundation.



Mark Roschewski, MD

Memorial Sloan Kettering Cancer Center

Mark Roschewski M.D is a clinician scientist who is currently an Attending Physician at Memorial Sloan Kettering Cancer in New York City. He began his career at Walter Reed Army Medical Center as an active-duty physician in the Army. After completing 12 years of active-duty Army service time, he transferred to the U.S. Public Health Service and joined the faculty at the NCI until 2025. He retired from the USPHS as a CAPT in 2023.

Dr. Roschewski earned his B.A. degrees at University of Notre Dame and received his medical degree from the University of Nebraska Medical Center in Omaha, NE. He completed both internship and residency in internal medicine at Eisenhower Army Medical Center in Augusta, GA and hematology-oncology fellowship in medical oncology at the Walter Reed Army Medical Center in Washington, DC.

The primary goal of his research team is to translate novel findings from the molecular biology of lymphoma into innovative therapies for lymphomas such as large B-cell lymphoma (LBCL), Burkitt's lymphoma, follicular lymphoma, mantle cell lymphoma, EBV-associated lymphomas, and CNS lymphomas. He pioneered studies to develop highly effective therapy for subtypes of LBCL such as primary mediastinal B-cell lymphoma and Burkitt's lymphoma. In addition, he conducted studies that demonstrated the effectiveness of targeted therapies including inhibitors of Bruton tyrosine kinase (Btk), ibrutinib in both primary and secondary CNS lymphomas, and recently he co-developed a multi-targeted regimen (ViPOR) for relapsed LBCL. His translational research interests include studying circulating tumor DNA (ctDNA) as a predictive and prognostic biomarker in LBCL and other lymphoma subtypes.

Dr. Roschewski is frequently invited to give presentations on his research to both national and international audiences, and he has published in high-impact scientific journals. He is often a reviewer for various scientific journals including New England Journal of Medicine, Blood, Cancer Cell, Nature, Lancet Oncology, and Journal of Clinical Oncology. He currently joined the editorial board of Blood in 2024.



Planning Committee Biographies

Eduardo Sotomayor, MD

Tampa General Hospital

Dr. Sotomayor is the Senior Vice President and Executive Director of Tampa General Hospital Cancer Institute as well as a Professor of Medicine at Morsani College of Medicine, University of South Florida in Tampa. Previously, he was the Director of the George Washington University Cancer Center and before he served as the Susan and John Sykes Endowed Chair in Hematologic Malignancies at Moffitt Cancer Center and Professor of Oncologic Sciences and of Pathology and Cell Biology at the University of South Florida College of Medicine in Tampa.



He received his MD degree from Federico Villarreal National University School of Medicine in Lima, Peru. He completed a residency training in Internal Medicine at Jackson Memorial Hospital/University of Miami School of Medicine in Florida, followed by a fellowship in Medical Oncology at Johns Hopkins University in Baltimore, Maryland. His translational/clinical research for the past twenty years has focused on the field of cancer immunology and immunotherapy with special emphasis in B-cell malignancies. He has published more than 130 manuscripts, including seminal publications in top tier journals such as Nature Medicine, Nature Immunology, Immunity, Cancer Cell, Proceedings of the National Academy of Sciences, Journal of Clinical Investigations, Blood, Cancer Research and Journal of Immunology. He has received multiple grants from the Lymphoma Research Foundation (LRF) and the National Cancer Institute. He is now leading TGH Cancer Institute in its pursuit of NCI-designation (P30 Grant) within the decade.

Dr. Sotomayor is a member of the Scientific Advisory Board, Lymphoma Research Foundation, member of the Mantle Cell Lymphoma Consortium. He has served as member of the Science Policy and Government Affairs Committee, American Association for Cancer Research (AACR), Chair, Latin American Regional Advisory Group, International Affairs Committee, AACR, member of the Hematologic Malignancies Task Force at AACR, member Cancer Immunology and Immunotherapy (CIMI) Steering Committee at AACR, member of the FLASCO Board of Directors, and former member of the National Cancer Institute, Subcommittee A, Cancer Centers. In 2017, he received the Lifetime Achievement Award from the Center to Reduce Cancer Health Disparities at NCI.

Faculty Biographies

Jason Avigan, MD

NYU Langone Health

Dr. Jason Avigan is a second-year Hematology/Medical Oncology Fellow at NYU Grossman School of Medicine, focusing on lymphoma clinical research and clinical trials. Dr. Avigan earned his MD with Honors in Biochemistry and Molecular Pharmacology from NYU before training in the Clinical Investigator Track in NYU's Internal Medicine residency. He was awarded the resident research award for his work with Dr. Gareth Morgan and Dr. Faith Davies on the bone marrow stromal microenvironment in a mouse model of multiple myeloma. His clinical and research interests now center on care for patients with indolent and aggressive lymphomas. He is particularly interested in toxicity mitigation in aggressive lymphomas: curing younger patients with less long-term toxicity, and expanding curative options in elderly patients unfit for standard approaches. In June 2026, he received the Fellow of the Year Award for Hematology/Medical Oncology at NYU.



Nilanjan Ghosh, MD, PhD

Atrium Health Levine Cancer Institute

Nilanjan Ghosh, MD, PhD, FACP is the Kerry and Simone Vickar Family Foundation Endowed Chair of Hematology, Chief of the lymphoma section at Levine Cancer Institute, and Professor of Cancer Medicine at the Wake Forest University School of Medicine, Charlotte, NC. His clinical and research interests are in lymphoma and CLL, where he is a principal investigator on innovative clinical trials and has published extensively in this area.



Faculty Biographies

Andrew Ip, MD

Hackensack Meridian Health John Theurer Cancer Center

I am a clinical investigator, with a clinical focus on lymphoma, specifically diffuse large B-cell lymphoma. I have been part of a busy lymphoma group at Hackensack since September 2019, with involvement in multiple trials as PI or sub-investigator studying CAR-T or BiTE therapies. Caring for patients has always driven me to find the best way to treat and manage their cancer, and I am fiercely committed to offering the best and highest quality of care to my patients and in general for the cancer community. To that end, my long-term research interests revolve around studying novel therapeutics for aggressive non-Hodgkin lymphomas, and the use of data analytics to improve cancer outcomes.

During my time at Hackensack, I have been a part of and now lead an Outcomes and Value Care Division for our cancer center since 2021. I have a large experience analyzing large real-world clinical and genomic datasets with my background, and have published over 40 papers in this regard in the past 7 years. Many of these papers are regarding the safety, efficacy, and further understanding of resistance or relapse during or after use of CAR-T or BiTE therapies. I am extremely committed to move the field forward, through research and education initiatives, to help implement these immunotherapies safely and broadly for the community.



Anita Kumar, MD

Memorial Sloan Kettering Cancer Center

Anita Kumar, MD, is an associate attending at Memorial Sloan Kettering Cancer Center (MSKCC) in the Department of Medicine, Lymphoma Service. She completed her bachelor of arts degree in biochemical sciences at Harvard College, graduating cum laude. She proceeded to Feinberg School of Medicine, Northwestern University, where she received her doctor of medicine degree. Dr Kumar then served as an intern and resident in internal medicine at Brigham and Women's Hospital and completed a fellowship in hematology and medical oncology at MSKCC. She joined the faculty of MSKCC in 2014, where she leads the mantle cell lymphoma research program.

Dr Kumar's clinical interests involve the care of patients with Hodgkin and non-Hodgkin lymphoma. Dr. Kumar is a clinical investigator with a research focus in mantle cell lymphoma (MCL) and in the clinical applications of minimal residual disease (MRD) assessment in B-cell non-Hodgkin lymphomas (NHL). As the leader of the MCL research program at MSK, she strives to develop risk-adapted treatments in MCL that are informed by baseline prognostic testing and apply novel molecular response tools (such as MRD testing). She serves as a principal investigator for multiple clinical trials incorporating novel immunotherapies and biologically targeted agents. Practicing in a community-based clinic in New Jersey, she is passionate about developing treatments that can be administered easily in the ambulatory setting and is committed to expanding access to novel therapeutics for lymphoma patients.



Faculty Biographies

Anju Nohria, MD

NYU Langone Health

Anju Nohria, MD, MSc, is a cardiologist specializing in cardio-oncology and advanced heart failure and transplantation. She received her MD from Harvard Medical School and an MSc in Clinical Epidemiology from the Harvard School of Public Health. She completed her internal medicine residency and chief residency at Yale-New Haven Hospital, followed by fellowships in cardiovascular medicine and advanced heart failure and transplantation at Brigham and Women's Hospital.



Dr. Nohria previously served as Director of the Cardio-Oncology Program at Dana-Farber Brigham Cancer Center and is now Director of the Cardio-Oncology Program at NYU Langone Hospitals–Manhattan and a member of the faculty at NYU Grossman School of Medicine. A leader in the field of cardio-oncology, Dr. Nohria has published extensively and has contributed to the development of clinical approaches to preventing, identifying, and managing cardiovascular complications of cancer therapy. Her research focuses on understanding risk factors for cardiotoxicity and developing pharmacologic and nonpharmacologic strategies to prevent cardiovascular disease and improve functional capacity and outcomes in patients with cancer and cancer survivors.

Luca Paruzzo, MD

University of Pennsylvania

Luca Paruzzo, MD, is a physician-scientist with a research focus on T-cell-mediated immunotherapies for hematologic malignancies. He completed his Hematology/Oncology training at the University of Torino in Italy, followed by postdoctoral training in translational cellular therapy research in Dr. Marco Ruella's laboratory at the University of Pennsylvania. He is currently an Instructor of Medicine at the University of Pennsylvania and a member of the Lymphoma Program led by Dr. Stephen Schuster. His research focuses on understanding the determinants of CAR T-cell efficacy, toxicity, and long-term outcomes, with the goal of improving and personalizing cellular therapies for patients with hematologic malignancies.



Faculty Biographies

Sarah Rutherford, MD

NYU Langone Health

Dr. Sarah Rutherford is an Associate Professor of Medicine (Clinical) at NYU Langone Health. She is a graduate of the University of Virginia School of Medicine. She completed Internship and Residency in Internal Medicine at Thomas Jefferson University Hospital and Fellowship in Hematology/Oncology at New York-Presbyterian Hospital/Weill Cornell Medical College. Her research focuses on novel approaches in Hodgkin, large B-cell and follicular lymphomas. She has experience taking care of patients with a variety of lymphomas and CLL.



Stephen Schuster, MD,

University of Pennsylvania

Stephen J. Schuster, MD is the Robert and Margarita Louis-Dreyfus Professor of CLL and Lymphoma and a professor of medicine at the University of Pennsylvania. He is also the Director of the Lymphoma Program and Director of Lymphoma Translational Research at the Abramson Cancer Center. After graduating AOA from Jefferson Medical College and completing his residency at Pennsylvania Hospital, Dr. Schuster completed clinical and research fellowships at the Cardeza Foundation for Hematologic Research. In 1989, he became a member of the Cardeza Foundation at Jefferson Medical College.

Dr. Schuster joined the University of Pennsylvania in 1998. Since then, his research has focused on the development and application of novel immunotherapies for B-cell lymphomas and CLL, including autologous tumor-derived vaccines, autologous costimulated T-cells, radioimmunotherapy, monoclonal antibody therapy, bispecific antibody therapy, and adoptive immunotherapy using chimeric antigen receptor modified T cells (CAR-T cells).




Faculty Biographies

Pratik Shah, MD

Northwell Health

Dr. Pratik Shah is an Attending Physician in Hematology/Oncology at the R.J. Zuckerberg Cancer Center. He received his medical degree from the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, following his undergraduate studies at Hofstra University. His comprehensive post-graduate training, including Internal Medicine residency and Hematology/Oncology fellowship, was completed at Northwell Health North Shore University Hospital/Long Island Jewish Hospital. Dr. Shah's clinical and research focus lies in chronic lymphocytic leukemia (CLL) and monoclonal B-cell lymphocytosis (MBL). We are pleased to welcome him to Lymphoma Rounds today to present a case.





Research Foundation

National Headquarters

Wall Street Plaza

88 Pine Street, Suite 2400

New York, NY 10005

Lymphoma Resource Center

(800) 500-9976

connect@lymphoma.org

lymphoma.org